Download PDF
Dialyse aktuell 2017; 21(06): 283-289
DOI: 10.1055/s-0043-113493
Schwerpunkt | Dialyse
© Georg Thieme Verlag Stuttgart · New York

Regionale Zitratantikoagulation

Was ist wichtig bei Hämodialyse und Hämofiltration?
Christian Forster Prof. Dr. med.
1   Medizinische Klinik 4 – Nephrologie und Hypertensiologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
,
Gunnar Schley Prof. Dr. med.
1   Medizinische Klinik 4 – Nephrologie und Hypertensiologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
,
Carsten Willam Prof. Dr. med.
1   Medizinische Klinik 4 – Nephrologie und Hypertensiologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
› Author Affiliations
Further Information

Publication History

Publication Date:
29 August 2017 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die regionale Zitratantikoagulation ist inzwischen zum oftmals bevorzugten Antikoagulationsverfahren in der chirurgischen und anästhesiologischen Intensivmedizin geworden. Dem Nachteil des höheren Aufwandes und der Bedenken wegen Nebenwirkungen stehen die Vorteile gegenüber, weniger Blutverlust zu erleiden, höhere Filterlaufzeiten und konsekutiv höhere Dialysedosen zu erreichen und auch blutungsgefährdete Patienten behandeln zu können. Für die intermittierenden Verfahren gibt es mittlerweile ebenfalls zahlreiche Protokolle, die jedoch als weniger validiert gelten können. Die Weiterentwicklung der Zitratantikoagulation verspricht auch vorteilhaft für den intermittierenden Dialysebereich und der Therapie chronischer Dialysepatienten zu sein.

 
  • 1 Schmitz M, Heering PJ, Hutagalung R. et al. Treatment of acute renal failure in Germany: Analysis of current practice. Medizinische Klinik, Intensivmedizin und Notfallmedizin 2015; 110: 256-263
    CrossrefGoogle Scholar
  • 2 KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2: S1-S138
    CrossrefGoogle Scholar
  • 3 Morita Y, Johnson RW, Dorn RE. et al. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 1961; 242: 32-43
    CrossrefGoogle Scholar
  • 4 Mehta RL, McDonald BR, Aguilar MM. et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981
    CrossrefGoogle Scholar
  • 5 Gattas DJ, Rajbhandari D, Bradford C. et al. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med 2015; 43: 1622-1629
    CrossrefPubMedGoogle Scholar
  • 6 Kutsogiannis DJ, Gibney RT, Stollery D. et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367
    CrossrefGoogle Scholar
  • 7 Liu C, Mao Z, Kang H. et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care 2016; 20: 144
    CrossrefPubMedGoogle Scholar
  • 8 Nurmohamed SA, Vervloet MG, Girbes AR. et al. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood purification 2007; 25: 316-323
    CrossrefGoogle Scholar
  • 9 Morabito S, Pistolesi V, Tritapepe L. et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012; 16: R111
    CrossrefGoogle Scholar
  • 10 Schilder L, Nurmohamed SA, ter Wee PM. et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol 2014; 15: 19
    CrossrefGoogle Scholar
  • 11 Oudemans-van Straaten HM, Bosman RJ, Koopmans M. et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552
    CrossrefGoogle Scholar
  • 12 Hetzel GR, Schmitz M, Wissing H. et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-239
    CrossrefPubMedGoogle Scholar
  • 13 Schilder L, Nurmohamed SA, Bosch FH. et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472
    CrossrefGoogle Scholar
  • 14 Stucker F, Ponte B, Tataw J. et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015; 19: 91
    CrossrefGoogle Scholar
  • 15 Gradwohl-Matis I, Franzen M, Seelmaier C. et al. Renal replacement therapy with regional citrate anticoagulation as an effective method to treat hypercalcemic crisis. ASAIO J 2015; 61: 219-223
    CrossrefGoogle Scholar
  • 16 Link A, Klingele M, Speer T. et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care 2012; 16: R97
    CrossrefGoogle Scholar
  • 17 Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 748-752
    CrossrefGoogle Scholar
  • 18 Nurmohamed SA, Jallah BP, Vervloet MG. et al. Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study. BMC Nephrol 2013; 14: 89
    CrossrefGoogle Scholar
  • 19 Durao MS, Monte JC, Batista MC. et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med 2008; 36: 3024-3029
    CrossrefGoogle Scholar
  • 20 Schultheiß C, Saugel B, Phillip V. et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012; 16: R162
    CrossrefGoogle Scholar
  • 21 Slowinski T, Morgera S, Joannidis M. et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19: 349
    CrossrefPubMedGoogle Scholar
  • 22 Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol 2014; 9: 2173-2188
    CrossrefGoogle Scholar
  • 23 Chenouard A, Liet JM. Regional Citrate Anticoagulation: Beware of Recirculation Phenomenon. Ther Apher Dial 2017; 21: 206-207
    CrossrefGoogle Scholar
  • 24 Gubensek J, Buturovic-Ponikvar J, Ponikvar R. Regional citrate anticoagulation for single-needle hemodialysis: a prospective clinical study. Blood Purif 2007; 25: 454-456
    CrossrefGoogle Scholar
  • 25 Buturovic-Ponikvar J, Cerne S, Gubensek J, Ponikvar R. Regional citrate anticoagulation for hemodialysis: calcium-free vs. calcium containing dialysate - a randomized trial. Int J Artif Organs 2008; 31: 418-424
    CrossrefGoogle Scholar
  • 26 Stegmayr BG, Jonsson P, Mahmood D. A significant proportion of patients treated with citrate containing dialysate need additional anticoagulation. Int J Artif Organs 2013; 36: 1-6
    CrossrefGoogle Scholar
  • 27 Sands JJ, Kotanko P, Segal JH. et al. Effects of citrate acid concentrate (citrasate(R)) on heparin N requirements and hemodialysis adequacy: a multicenter, prospective noninferiority trial. Blood Purif 2012; 33: 199-204
    CrossrefGoogle Scholar
  • 28 Grundström G, Christensson A, Alquist M. et al. Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility. BMC Nephrol 2013; 14: 216
    CrossrefGoogle Scholar
  • 29 Monchi M, Berghmans D, Ledoux D. et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265
    CrossrefGoogle Scholar
  • 30 Morgera S, Scholle C, Melzer C. et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98: c35-c40
    CrossrefGoogle Scholar
  • 31 Gubensek J, Buturovic-Ponikvar J, Skofic N, Ponikvar R. Regional citrate anticoagulation for intermittent predilution online hemofiltration. Ther Apher Dial 2009; 13: 306-309
    CrossrefGoogle Scholar
  • 32 Beige J, Kuhlmann U. Durchführung intermittierender Dialysen mit zitratbasierter regionaler Antikoagulation nach den Regeln des Medizinproduktegesetzes. Positionspapier der Deutschen Gesellschaft für Nephrologie. Nephrologe 2017; 12: 43-44
    CrossrefGoogle Scholar